Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA): 7 pipeline candidates · 3 upcoming catalysts · ~10 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
10.0 months
D/E 0.22 · 0% dilution
Lead: Phase 3
7 candidates
3 upcoming, next in ~440d
1 buy · 9 sells (180d)
A transparent, data-derived signal for Intellia Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$134.7M
Quarterly Burn
$117.3M
Runway
10.0 mo
Revenue
$15.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| Allogeneic CAR T cell therapy | Preclinical |
| biological ntla-2002 | Phase 1/Phase 2 |
| KYV-201 | Preclinical |
| lonvoguran ziclumeran | Phase 3 |
| nexiguran ziclumeran | Phase 3 |
| NTLA-2001 | Phase 1 |
| NTLA-2002 | Phase 3 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
306
Total value held
$1.49B
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 14,509,247 | $186.0M |
| blackrock, inc. | 12,155,806 | $155.8M |
| vanguard capital management llc | 10,168,210 | $130.4M |
| state street corp | 6,922,676 | $88.7M |
| vanguard portfolio management llc | 6,223,325 | $79.8M |
| d. e. shaw & co., inc. | 5,728,177 | $73.4M |
| two sigma investments, lp | 4,705,901 | $60.3M |
| regeneron pharmaceuticals, inc. | 3,702,995 | $47.5M |
| geode capital management, llc | 2,851,472 | $36.6M |
| susquehanna international group, llp | 2,702,665 | $34.6M |
Showing top 10 of 306 institutional holders of Intellia Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Intellia Therapeutics, Inc.'s pipeline?
Intellia Therapeutics, Inc. (NTLA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Intellia Therapeutics, Inc.'s lead drug candidate?
Intellia Therapeutics, Inc.'s most advanced tracked candidate is Allogeneic CAR T cell therapy (Preclinical) for Immuno-oncology and hematological and solid tumors.
What is Intellia Therapeutics, Inc.'s next catalyst?
Intellia Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the " — expected September 1, 2027.
What is Intellia Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Intellia Therapeutics, Inc. has approximately 10.0 months of cash runway.
What is Intellia Therapeutics, Inc.'s market capitalization?
Intellia Therapeutics, Inc.'s market capitalization is approximately $1.7B.
Get the full picture on Intellia Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.